Sinclair Pharma has reported H1 2017 revenues of £ Revenue for the six months ended June 30 rose to 20.1 million pounds from 17.3 million pounds a year ago, while its pre-tax loss narrowed to 7.2 million pounds from a loss of 8.6 million pounds a year ago. 20.1m ($27.2m), an increase of 16% on last year's figure of £17.3m. The growth is attributed to strong demand for Sinclair's aesthetic dermatology products in Brazil. In the UK, sales rose by 12% year-on-year and were up 19% compared with 2016. Even better results are expected in the second half of the year, according to CEO Chris Spooner.
Sinclair Pharma has reported H1 2017 revenues of £ 20.1m ($27.2m), an increase of 16% on last year's figure of £17.3m. The growth is attributed to strong demand for Sinclair's aesthetic dermatology products in Brazil. In the UK, sales rose by 12% year-on-year and were up 19% compared with 2016. Even better results are expected in the second half of the year, according to CEO Chris Spooner.